论文部分内容阅读
目的:对布地奈德混悬液联合沐舒坦雾化吸入治疗新生儿肺透明病的疗效进行观察。方法:给予对照组患儿进行常规治疗手段,通过氯化钠对沐舒坦进行稀释,以便于新生儿的氧雾化吸收。观察组在对照组的基础上,应用布地奈德混悬液,通过氯化钠进行稀释,将布地奈德与沐舒坦保持在2 ml,对新生儿进行氧雾化吸入,2次/d,维持10 d的治疗时间。将患儿的临床疗效分为显著、有效以及无效。结果:观察组总有效67例,占95.71%;对照组总有效61例,占87.14%。观察组总有效率明显高于对照组,两组数据具有统计学意义(P<0.05)。结论:布地奈德混悬液联合沐舒坦雾化吸入的药物治疗手段要较之单一进行沐舒坦的治疗手段具有更好的临床效果,适用于新生儿肺透明病的临床治疗与应用。
OBJECTIVE: To observe the curative effect of budesonide suspension combined with mucosolvan inhalation in the treatment of neonatal pulmonary transplanopathy. Methods: Children in control group were given routine treatment, and mucosolvan was diluted by sodium chloride in order to facilitate neonatal oxygen atomization. Observation group based on the control group, the use of budesonide suspension, diluted by sodium chloride, budesonide and ambroxol were kept at 2 ml, neonatal aerosol inhalation, 2 times / d, Maintain the treatment time of 10 d. The clinical efficacy of children were divided into significant, effective and ineffective. Results: The total observation group 67 cases, accounting for 95.71%; control group, 61 cases were effective, accounting for 87.14%. The total effective rate in the observation group was significantly higher than that in the control group, with statistical significance (P <0.05). Conclusion: The combination of budesonide suspension and mucosolvan inhalation is more effective than mucosolvan alone in the treatment of pulmonary transplanopathies in neonates.